VP, Medical Affairs International and Japan
The VP, Medical Affairs International and Japan (EMEAC, LATAM, APAC, Japan) will provide overall leadership and strategic planning for all Medical Affairs activities throughout the International and Japan region including disease area lead, scientific communications, operations and functional leadership of the relevant country-based Medical Directors.
This position will provide leadership in building and executing the appropriate Medical Affairs strategy for the Alexion portfolio in International and Japan. The focus will be on setting the direction for the International and Japan Medical Affairs team in terms of Regional strategy, operations and processes and execution at the country level.
Key activities and responsibilities include:
- Sets the overall vision for, and the leads the International and Japan Medical Affairs team, attracting, engaging and retaining key talent needed to accomplish objectives
- Leads the development and implementation of the country Medical Affairs strategy and activities, in line with best clinical practices and overall corporate objectives
- Provides strategic input and thought leadership into regional launch and lifecycle management plans, including leading the implementation of medical affairs practices to assess new indications, the treating community, patient pathways, identifying sites for clinical research and to develop a thorough understanding of the disease areas
- Ensures all Medical Affairs activities comply with current pharmaceutical regulations, Alexion internal policies and procedures, Alexion Code of Conduct and follow state of the art governance, reporting systems and structures
- Develops and continuously maintains the highest scientific and medical expertise of all Medical Affairs employees ensuring they are acknowledged internally and externally as experts
- Systematically assesses medical education needs cross-functionally and implements appropriate medical education programs for commercial teams and other functions
- Significant (10+ years) experience in a biotech or pharmaceutical company with increasing levels of leadership responsibility within R&D and/or Medical Affairs. Prior launch experience would be an advantage.
- Experience leading Medical Affairs in International and Japan countries and/or above-country experience with demonstrated track record of setting the medical strategies that align with commercial and medical needs is requires. US experience would be an advantage.
- Leadership experience in a global Medical Affairs organization
- Deep knowledge of the International and Japan market, including its Regulatory and Compliance requirements
- Clinical Operations experience (design and implementation of clinical trials) and proven ability to manage budget and resources
- Experience working effectively in a matrix environment that includes interactions with multiple stakeholder groups (e.g. commercial, regulatory, clinical operations, clinical development, etc.)
- Experience developing and managing a large geographically disperse team, making optimal resource tradeoff decisions, and driving change to achieve desired outcomes. Country leadership experience is an advantage
- Demonstrated ability to successfully engage external stakeholder, including thought leaders and regulators
- Has a strong track record of people management and leadership skills acquired in a multicultural environment
- Exhibits composure and flexibility to face changing conditions and high pressure
- Has excellent oral and written communication as well as presentation skills
- Is fluent in both written and oral English; fluency in other languages is highly desirable
- Is willing to undertake extensive international travel as required
- Must have a PhD, Pharm D – MD preferred
Some opportunities happen only once in a lifetime – like a job where you have the extraordinary opportunity to change lives. At Alexion, such opportunities arise through our unwavering mission to serve patients and families affected by rare diseases. These patients are our guiding star, and we act with integrity, urgency, and discipline because we know their lives are at stake.
Alexion is a global biopharmaceutical company focused on serving patients and families affected by rare diseases through the discovery, development and commercialization of life-changing therapies. As the global leader in complement biology and inhibition for more than 20 years, Alexion has developed and commercializes two approved complement inhibitors to treat patients with paroxysmal nocturnal hemoglobinuria (PNH) as well as the first and only approved complement inhibitor to treat atypical hemolytic uremic syndrome (aHUS), anti-acetylcholine receptor (AchR) antibody-positive generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD). Alexion also has two highly innovative enzyme replacement therapies for patients with life-threatening and ultra-rare metabolic disorders, hypophosphatasia (HPP) and lysosomal acid lipase deficiency (LAL-D). In addition, the company is developing several mid-to-late-stage therapies, including a second complement inhibitor, a copper-binding agent for Wilson disease and an anti-neonatal Fc receptor (FcRn) antibody for rare Immunoglobulin G (IgG)-mediated diseases as well as several early-stage therapies, including one for light chain (AL) amyloidosis and a second anti-FcRn therapy. Alexion focuses its research efforts on novel molecules and targets in the complement cascade and its development efforts on the core therapeutic areas of hematology, nephrology, neurology, and metabolic disorders. Alexion has been named to the Forbes’ list of the World’s Most Innovative Companies seven years in a row and is headquartered in Boston, Massachusetts’ Innovation District. The company also has offices around the globe and serves patients in more than 50 countries. Further information about Alexion can be found at: www.alexion.com.